Week in Review: WuXi PharmaTech Co., Ltd. Contributes to Syros Pharma Funding
Published: Apr 29, 2013
April 27, 2013 -- Syros Pharmaceuticals of Boston raised $30 million to develop cancer treatments from WuXi PharmaTech and other investors; a subsidiary of Hua Han Bio-Pharma signed a framework agreement to set up a JV with China’s National Vaccine & Serum Institute; Tasly Pharma paid $240 million to acquire Jiangsu TaslyDiyi Pharma, a maker of chemical drugs; 3SBio received a much-higher offer from the consortium that is offering to take the company private, though the consortium is alleged to have discouraged other bids; Takeda and Sanofi agreed to co-promote Takeda’s Alogliptin, a DPP-4 treatment for type 2 diabetes, in China; Eisai announced plans to build a second production facility in Suzhou; and China scientists used lasers as optical tweezers to pick apart a blockage in the capillaries of a mouse ear, cell by cell. More details….
Stock Symbols: (NYSE: WX) (HK: 00587) (SHA: 600535) (NSDQ: SSRX) (TO: 4502) (NYSE: SNY) (TO: 4523)